Back to Search
Start Over
Isorhamnetin: A review of pharmacological effects
- Source :
- Biomedicine & Pharmacotherapy, Vol 128, Iss, Pp 110301-(2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Isorhamnetin is one of the most important active ingredients in the fruits of Hippophae rhamnoides L. and the leaves of Ginkgo biloba L., which possesses extensive pharmacological activities. At present, there have been numerous investigations on isorhamnetin, which has the effects of cardiovascular and cerebrovascular protection, anti-tumor, anti-inflammatory, anti-oxidation, organ protection, prevention of obesity, etc. The related mechanisms involve the regulation of PI3K/AKT/PKB, NF-κB, MAPK and other signaling pathways as well as the expression of related cytokines and kinases. Isorhamnetin has a high value of development and application. However, the investigations on its mechanism of action are limited and lack of detailed scientific validation. The manuscript reviewed the pharmacological effects of isorhamnetin and related mechanisms of action for the development of its medicinal properties further.
- Subjects :
- 0301 basic medicine
MAPK/ERK pathway
RM
RM1-950
Pharmacology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Hippophae
Animals
Humans
Effect
Medicine
Isorhamnetin
Protein kinase B
PI3K/AKT/mTOR pathway
Flavonoids
Plants, Medicinal
biology
Plant Extracts
business.industry
Mechanism (biology)
Ginkgo biloba
General Medicine
biology.organism_classification
Plant Leaves
030104 developmental biology
Gene Expression Regulation
Mechanism of action
chemistry
Fruit
030220 oncology & carcinogenesis
Quercetin
Mechanism
Therapy
Therapeutics. Pharmacology
medicine.symptom
Signal transduction
business
Signal Transduction
Subjects
Details
- ISSN :
- 07533322
- Volume :
- 128
- Database :
- OpenAIRE
- Journal :
- Biomedicine & Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....f45c3bf831e996e2cbdd680426b13cfc
- Full Text :
- https://doi.org/10.1016/j.biopha.2020.110301